An interventional study of TEER and Optimal Medical Therapy in Mitral Regurgitation, ATTR-Cardiomyopathy and Edge-to-Edge Mitral Valve Repair, sponsored by Medical University of Vienna. Recruiting at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Medical University of Vienna · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Mitral Valve Insufficiency with a site in Austria — 6 open to participants now, 8 under way, none of them phase 3. Mitral Valve Insufficiency · Austria.
Among the 15 studies in Mitral Valve Insufficiency with a site in Austria, this one is one of 2 that started in 2024, is one of 8 with no phase, and was the 13th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →6 of the 15 studies in Mitral Valve Insufficiency with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria, Germany, Italy and 1 more country
Ages 18+
LMU Klinikum · Sites in Austria, Belgium, France and 7 more countries
Ages 18+
Epygon · Sites in Austria, Italy, Serbia and 1 more country
Ages 60+
Universitätsklinikum Hamburg-Eppendorf · Sites in Austria, United States, Australia and 10 more countries
Ages 18+
Kephalios · Sites in Austria, Germany, Italy and 1 more country
Ages 21+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 106 is above the median of 69 across 280 interventional studies indexed under Mitral Valve Insufficiency.
Median enrollment 41 across the 8 interventional studies, 400 across the 7 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 9 most frequent:
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Medical University of Vienna has 4 studies filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
1 of the studies in Mitral Valve Insufficiency with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04898335LMU KlinikumTendyne European Experience Registry | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Mitral Valve Insufficiency with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
No previous study has evaluated the effectiveness of transcatheter edge-to-edge mitral valve repair (TEER) in patients with ATTR-associated cardiomyopathy (ATTR-CM) and significant mitral regurgitation, as this specific patient population was specifically excluded from previous large TEER trials. From a pathophysiological perspective, effective treatment of significant regurgitant volume and consecutive improvement of forward volume appears highly desirable in a condition with intrinsically low output. However, whether this translates into improved functional capacity, better quality of life, and better clinical outcomes compared to conservative heart failure management alone remains to be investigated.
MILLENNIAL is an investigator-initiated, multicentre, prospective, parallel-group, open-label, randomized controlled trial. Patients with proven ATTR-CM and concomitant significant (moderate-to-severe or severe) symptomatic mitral regurgitation, in whom the local heart team has ruled out mitral valve surgery and who are anatomically suitable for TEER, are randomized 1:1 to TEER plus optimal medical therapy (OMT) or OMT alone. Randomization is performed centrally with permuted blocks of variable size (4-8), stratified by the presence of significant tricuspid regurgitation and NYHA class ≥III. ATTR-specific therapy is allowed in both arms at the discretion of the treating physician. Cross-over is not permitted within the first year.
The primary endpoint is a hierarchical composite assessed at 12 months, analysed with the Finkelstein-Schoenfeld method (win ratio as effect measure, stratified by National Amyloidosis Centre stage): (1) all-cause mortality, (2) cumulative frequency of unplanned cardiovascular hospitalizations, (3) change from baseline in 6-minute walk distance (win threshold ≥30 m), (4) change from baseline in KCCQ Overall Summary score (win threshold ≥5 points). Heart transplantation, combined heart-liver transplantation and durable mechanical circulatory support are counted as death. Change in NT-proBNP is the key secondary endpoint; technical, device and procedural success (MVARC) are safety endpoints. Exploratory endpoints include intraprocedural invasive haemodynamics before and after device deployment and advanced echocardiographic indices of myocardial performance.
A sample size of 106 patients (53 per arm) provides 80% power at a two-sided alpha of 0.05 for an assumed win ratio of 2.1, including 10% cross-over and 5% drop-out. Study visits take place at baseline, 6 months (±7 days) and 12 months (±14 days). Interim analyses are performed after every 25 patients and reviewed by an independent data monitoring committee; a pre-specified futility analysis is performed once 50 patients have completed 12-month follow-up (stop if conditional power \<10%).
The criteria were revised on the registry on Oct 16, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria (all must be absent)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TEER + Optimal Medical Therapy
Device: TEER · Other: Optimal Medical Therapy
Optimal Medical Therapy alone
Other: Optimal Medical Therapy
Transcatheter edge-to-edge mitral valve repair under general anaesthesia with transoesophageal echocardiographic and fluoroscopic guidance; up to three newer-generation MitraClip (NTR, XTR; Abbott) or PASCAL (Edwards Lifesciences) devices to maximally reduce mitral regurgitation. Intraprocedural invasive haemodynamic measurements before and after device deployment.
Optimal medical therapy according to the current understanding of heart failure management in ATTR-CM (careful volume management, rate/rhythm control in atrial fibrillation, anticoagulation where indicated). ATTR-specific therapy (e.g. tafamidis, acoramidis) is allowed but not mandatory in both arms at the discretion of the treating physician; all heart failure and ATTR-specific medication is recorded at every visit.
Hierarchical composite of all-cause mortality, cumulative frequency of unplanned cardiovascular-related hospitalizations, change from baseline in 6-minute walk distance, and change from baseline in KCCQ Overall Summary score through month 12
Each subject in the TEER+OMT group is compared with each subject in the OMT group in a pairwise manner, within strata defined by National Amyloidosis Centre disease stage (I, II, III) at baseline, in hierarchical order: (1) all-cause mortality (heart transplantation, combined heart-liver transplantation and implantation of a durable mechanical cardiac-assist device count as death); (2) cumulative frequency of unplanned cardiovascular-related hospitalizations, compared over the shorter follow-up time of the pair; (3) change from baseline in 6-minute walk distance, a difference of ≥30 m defining a win (smaller differences are ties); (4) change from baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary score (0-100, higher = better health status), a difference of ≥5 points defining a win. Statistical significance is tested with the Finkelstein-Schoenfeld method at a two-sided alpha of 0.05; the win ratio quantifies the treatment effect.
Time frame: 12 months
Change from baseline in NT-proBNP (key secondary endpoint)
Change from baseline in N-terminal pro-B-type natriuretic peptide (pg/mL), analysed with a mixed-effects model for repeated measures / analysis of covariance with treatment group and visit as fixed effects and the baseline value as covariate.
Time frame: Baseline, 6 months and 12 months
Technical, device, and procedural success of TEER (in the TEER group only)
Technical, device, and procedural success of TEER as defined according to the definitions of the Mitral Valve Academic Research Consortium (MVARC)
Time frame: Technical success at exit from the procedure room; device and procedural success at 6 and 12 months
Change from baseline in echocardiographic indices of myocardial performance and remodelling
Change from baseline in left ventricular ejection fraction, forward stroke volume, global longitudinal strain, tissue Doppler-derived systolic and diastolic velocities and diastolic function indices, left atrial strain, myocardial contraction fraction (left ventricular stroke volume/myocardial volume) and left ventricular stroke work index, assessed by a blinded echocardiographic core laboratory.
Time frame: Baseline, 6 months and 12 months
Acute intraprocedural change in invasive haemodynamics (TEER group only)
Change in forward stroke volume, cardiac output and cardiac index, right atrial pressure, pulmonary artery pressures, pulmonary capillary wedge pressure, and pulmonary and systemic vascular resistance measured with standard catheterization laboratory equipment immediately before and after device deployment. Sub-analyses will assess cut-offs of acute haemodynamic change that identify responders with regard to myocardial performance and clinical outcome.
Time frame: Intraprocedural (immediately before and after device deployment)
Plan to share: No
Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.
Of 144 interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 108. This study's planned 47 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →